(BPT) - This content was sponsored by GSK. Nadine is a real patient who was on treatment at the time of these interviews. GSK paid for her time and expenses
Janssen: New Data Demonstrate the Benefits of Early Use of UPTRAVI (selexipag) in Delaying Disease Progression in a Broad Population of Patients with Pulmonary Arterial Hypertension (PAH) finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in Delaying Disease Progression in a Broad Population of Patients with Pulmonary Arterial Hypertension (PAH) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio
- UCB reinforces commitment to delivering increased patient value by presenting latest research findings in epilepsy, myasthenia gravis, and Parkinson s disease
- Nine scientific presentations illustrate UCB s dedication to neurology and highlight the importance of gathering patient insight to transform patient experience
- UCB will also host a virtual symposium to discuss the clinical features of rare autoimmune neuromuscular diseases such as generalized myasthenia gravis, held on Tuesday, April 20, 09:00 - 10:00 ET
News provided by
Share this article
Share this article